Related Experiment Videos
Targeted chemotherapy: chronic myelogenous leukemia as a model
Nima Sharifi1, Richard A Steinman
1Department of Medicine, University of Pittsburgh School of Medicine, PA 15213, USA.
Journal of Molecular Medicine (Berlin, Germany)
|April 27, 2002
Summary
Targeting the bcr-abl fusion gene offers a selective approach to treating chronic myelogenous leukemia (CML). Imatinib mesylate, a Bcr-Abl inhibitor, shows promise in CML therapy, representing a new era in anticancer drug development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Traditional cancer chemotherapy agents are cytotoxic but lack selectivity for cancer cells.
- Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome and the resulting bcr-abl fusion gene.
- The bcr-abl fusion gene is a unique target specific to CML cells.
Purpose of the Study:
- To review the molecular pathogenesis and current treatments for CML.
- To discuss the development of imatinib mesylate as a selective Bcr-Abl inhibitor.
- To highlight novel approaches in rational anticancer drug design.
Main Methods:
- Review of molecular pathogenesis of CML.
- Analysis of current CML treatment strategies.
- Discussion of imatinib mesylate development and clinical trial results.
Main Results:
- Advances in understanding CML molecular mechanisms have led to selective therapies.
- Imatinib mesylate has demonstrated promise in clinical trials for CML.
- Selective Bcr-Abl inhibition represents a significant advancement in CML treatment.
Conclusions:
- Targeting the bcr-abl fusion gene provides a specific therapeutic strategy for CML.
- Imatinib mesylate exemplifies a novel, rationally designed anticancer therapeutic.
- This approach signifies a paradigm shift in the development of targeted cancer drugs.